Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
1.100
0.00 (0.00%)
Apr 7, 2026, 9:31 AM EDT - Market open
Longeveron Revenue
In the year 2025, Longeveron had annual revenue of $1.20M, down -49.87%. Longeveron had revenue of $365.00K in the quarter ending December 31, 2025, a decrease of -39.47%.
Revenue (ttm)
$1.20M
Revenue Growth
-49.87%
P/S Ratio
26.86
Revenue / Employee
$31,553
Employees
38
Market Cap
32.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | -1.19M | -49.87% |
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 8.96M |
| Evaxion | 7.53M |
| Apollomics | 6.93M |
| Dyadic International | 3.09M |
| Pluri | 1.34M |
| ABVC BioPharma | 797.92K |
| Actinium Pharmaceuticals | 90.00K |
| INmune Bio | 50.00K |
LGVN News
- 20 days ago - Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - GlobeNewsWire
- 20 days ago - Longeveron Braces For Q4 Results Following Recent Funding Boost - Benzinga
- 26 days ago - Longeveron Announces Closing of Private Placement of up to $30 Million - GlobeNewsWire
- 27 days ago - Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal - Benzinga
- 5 weeks ago - Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell - GlobeNewsWire
- 7 weeks ago - Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - GlobeNewsWire
- 2 months ago - Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - GlobeNewsWire
- 2 months ago - Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - GlobeNewsWire